FGI-104: A broad-spectrum small molecule inhibitor of viral infection

American Journal of Translational Research

Volumn 1, Issue 1, 2009, Pages 87-98

  Kinch, Michael S ^a   Yunus, Abdul S ^a   Lear, Calli ^b   Mao, Hanwen ^a   Chen, Hanson ^a   Fesseha, Zena ^a   Luo, Guangxiang ^c   Nelson, Eric A ^d   Li, Limin ^a   Huang, Zhuhui ^e   Murray, Michael ^e   Ellis, William Y ^f   Hensley, Lisa ^b   Christopher Hennings, Jane ^d   Olinger, Gene G ^b   Goldblatt, Michael ^a  

^a Functional Genetics Inc   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d SOUTH DAKOTA STATE UNIVERSITY   (United States)

^e SOUTHERN RESEARCH INSTITUTE   (United States)

^f Walter Reed Army Institute for Research   (United States)

Author keywords

Antiviral; Ebola virus; HBV; HCV; Hepatitis; HIV

Indexed keywords

ANTIVIRUS AGENT; FGI 104; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTERIVIRUS; ARTICLE; CONTROLLED STUDY; COWPOX VIRUS; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SCREENING; EBOLA VIRUS; EXPERIMENTAL MOUSE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS CELL INTERACTION; VIRUS HEMORRHAGIC FEVER; VIRUS STRAIN;

EBOLA VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; PORCINE RESPIRATORY AND REPRODUCTIVE SYNDROME VIRUS;

EID: 68249120051     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Barbaro G, Scozzafava A, Mastrolorenzo A and Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005; 11: 1805-1843.
2. De Clercq E. Emerging antiviral drugs. Expert Opin Emerg Drugs 2008; 13: 393-416.
3. Locarnini S and Warner N. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antivir Ther 2007; 12: H15-H23.
4. Richman DD. Antiviral drug resistance. Antiviral Research 2006; 71: 117-121.
5. Crotty S and Andino R. Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin. Microbes Infect 2002; 4: 1301-1307.
6. Martins S, Ramos MJ and Fernandes PA. The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection. Curr Med Chem 2008; 15: 1083-1095.
7. Rameix-Welti MA, van der Werf S and Naffakh N. Sensitivity of H5N1 influenza viruses to oseltamivir: an update. Future Virol 2008; 3: 157-165.
8. Tran TT, van Doorn HR and de Jong MD. Human H5N1 influenza: Current insight into pathogenesis. Int J Biochem Cell Biol 2008; 40: 2671-2674.
9. Sloots TP, Whiley DM, Lambert SB and Nissen MD. Emerging respiratory agents: New viruses for old diseases? J Clin Virol 2008; 42: 233-243.
10. Parrish CR, Holmes EC, Morens DM, Park EC, Burke DS, Calisher CH, Laughlin CA, Saif LJ and Daszak P. Cross-species virus transmission and the emergence of new epidemic diseases. Microbiol Mol Biol Rev 2008; 72: 457-+.
11. Dong J, Olano JP, McBride JW and Walker DH. Emerging pathogens: Challenges and successes of molecular diagnostics. J Mol Diagn 2008; 10: 185-197.
12. Naghavi MH and Goff SP. Retroviral proteins that interact with the host cell cytoskeleton. Curr Opin Immunol 2007; 19: 402-407.
13. McLean JE, Ruck A, Shirazian A, Pooyaei-Mehr F and Zakeri ZF. Viral manipulation of cell death. Curr Pharm Des 2008; 14: 198-220.
14. Lehmann-Che J and Saib A. Early stages of HIV replication: How to hijack cellular functions for a successful infection. Aids Reviews 2004; 6: 199-207.
15. Carter CA. Tsg101: HIV-1's ticket to ride. Trends Microbiol 2002; 10: 203-205.
16. Perez OD and Nolan GP. Resistance is futile: assimilation of cellular machinery by HIV-1. Immunity 2001; 15: 687-690.
17. Li L and Cohen SN. Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 1996; 85: 319-329.
18. Williams RL and Urbe S. The emerging shape of the ESCRT machinery. Nat Rev Mol Cell Biol 2007; 8: 355-368.
19. Raiborg C, Rusten TE and Stenmark H. Protein sorting into multivesicular endosomes. Curr Opin Cell Biol 2003; 15: 446-455.
20. Falguieres T, Luyet PP, Bissig C, Scott CC, Velluz MC and Gruenberg J. In Vitro Budding of Intralumenal Vesicles into Late Endosomes Is Regulated by Alix and Tsg101. Mol Biol Cell 2008; 19: 4942-4955.
21. Pornillos O, Alam SL, Davis DR and Sundquist WI. Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein. Nat Struct Biol 2002; 9: 812-817.
22. Diviney S, Tuplin A, Struthers M, Armstrong V, Elliott RM, Simmonds P and Evans DJ. Hepatitis C virus cis-acting replication element forms a long-range RNA-RNA interaction with upstream RNA sequences in NS5B. J Virol 2008; 82: 9008-9022.
23. Wei XP, Decker JM, Liu HM, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu XY, Shaw GM and Kappes JC. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46: 1896-1905.
24. Wu WH, Fang Y, Farwell R, Steffen-Bien M, Rowland RRR, Christopher-Hennings J and Nelson EA. A 10-kDa structural protein of porcine reproductive and respiratory syndrome virus encoded by ORF2b. Virology 2001; 287: 183-191.
25. Nelson EA, Christopherhennings J, Drew T, Wensvoort G, Collins JE and Benfield DA. Differentiation of united-states and european isolates of porcine reproductive and respiratory syndrome virus by monoclonal-antibodies. J Clin Microbiol 1993; 31:3184-3189.
26. Fang Y, Rowland RRR, Roof M, Lunney JK, Christopher-Hennings J and Nelson EA. A full-length cDNA infectious clone of North American type 1 porcine reproductive and respiratory syndrome virus: Expression of green fluorescent protein in the Nsp2 region. J Virol 2006; 80: 11447-11455.
27. Towner JS, Paragas J, Dover JE, Gupta M, Goldsmith CS, Huggins JW and Nichol ST. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 2005; 332: 20-27.
28. Bray M, Davis K, Geisbert T, Schmaljohn C and Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178: 651-661.
29. Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis 2008; 197: S279-S293.
30. Done SH, Paton DJ and White MEC. Porcine reproductive and respiratory syndrome (PRRS): A review, with emphasis on pathological, virological and diagnostic aspects. Br Vet J 1996; 152: 153-174.
31. Li YF, Wang XL, Bo KT, Wang XW, Tang B, Yang BS, Jiang W and Jiang P. Emergence of a highly pathogenic porcine reproductive and respiratory syndrome virus in the Mid-Eastern region of China. Vet J 2007; 174: 577-584.
32. Martinez-Picado J and Martinez MA. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo. Virus Res 2008; 134: 104-123.
33. Duffy S, Shackelton LA and Holmes EC. Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet 2008; 9: 267-276.
34. Snowden FM. Emerging and reemerging diseases: a historical perspective. Immunol Rev 2008; 225: 9-26.
35. Bray M. Highly pathogenic RNA viral infections: Challenges for antiviral research. Antiviral Res 2008; 78: 1-8.
36. Martin-Serrano J, Zang T and Bieniasz PD. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med 2001; 7: 1313-1319.